Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Public ClinicalTrials.gov record NCT04389840. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2/3 Study to Evaluate the Safety and Efficacy of Dociparstat Sodium for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a randomized, double-blind, placebo-controlled Phase 2/3 study to evaluate the safety and efficacy of dociparstat sodium in adult patients with acute lung injury (ALI) due to Coronavirus Disease 2019 (COVID-19). This study was designed to determine if dociparstat sodium could accelerate recovery and prevent progression to mechanical ventilation in patients severely affected by COVID-19.
Study identification
- NCT ID
- NCT04389840
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 27 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 8, 2020 (Actual)
- Primary completion
- May 20, 2021 (Actual)
- Completion
- May 20, 2021 (Actual)
- Last update posted
- Aug 30, 2022
2020 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham | Birmingham | Alabama | 35294 | — |
| Advanced Pulmonary Research Institute/Wellington Regional Medical Center | Loxahatchee Groves | Florida | 33470 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Our Lady of the Lake | Baton Rouge | Louisiana | 70808 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| University Medical Center | New Orleans | Louisiana | 70112 | — |
| William Beaumont Hospital | Royal Oak | Michigan | 48073 | — |
| Ascension Macomb-Oakland Cardiovascular Research | Warren | Michigan | 48072 | — |
| Wake Forest Baptist Health | Winston-Salem | North Carolina | 27157 | — |
| Texas Health Harris Methodist Hospital Fort Worth | Dallas | Texas | 76104 | — |
| Ascension St. Francis Hospital | Milwaukee | Wisconsin | 53215 | — |
| Ascension All Saints Hospital | Racine | Wisconsin | 53405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04389840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2022 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04389840 live on ClinicalTrials.gov.